Related Experiment Video
Updated: Jul 9, 2026

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster
Published on: October 20, 2023
Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer's
Glenna A Dowling1, Robert L Burr, Eus J W Van Someren
1Department of Physiological Nursing, University of California at San Francisco, San Francisco, California 94143, USA. glenna.dowling@nursing.ucsf.edu
Objectives:
To test whether the addition of melatonin to bright-light therapy enhances the efficacy in treating rest-activity (circadian) disruption in institutionalized patients with Alzheimer's disease (AD).
Design:
Randomized, controlled trial.
Setting:
Two nursing homes in San Francisco, California.
Participants:
Fifty subjects (mean age 86) with AD.
Intervention:
Experimental subjects received 1 hour of morning light exposure (> or = 2,500 lux in gaze direction) Monday to Friday for 10 weeks and 5 mg melatonin (LM, n=16) or placebo (LP, n=17) in the evening. Control subjects (n=17) received usual indoor light (150-200 lux).
Measurements:
Nighttime sleep variables, day sleep time, day activity, day:night sleep ratio, and rest-activity parameters were determined using actigraphy.
Results:
Linear mixed models were employed to test the primary study hypotheses. No significant differences in nighttime sleep variables were found between groups. At the end of the intervention, the LM group showed significant improvement in daytime somnolence as indicated by a reduction in the duration of daytime sleep, an increase in daytime activity, and an improvement in day:night sleep ratio. The LM group also evidenced a significant increase in rest-activity rhythm amplitude and goodness of fit to the cosinor model.
Conclusion:
Light treatment alone did not improve nighttime sleep, daytime wake, or rest-activity rhythm. Light treatment plus melatonin increased daytime wake time and activity levels and strengthened the rest-activity rhythm. Future studies should resolve the question of whether these improvements can be attributed to melatonin or whether the two zeitgebers interact to amplify efficacy.
Related Concept Videos
Management of Insomnia
REM Sleep Behavior Disorder
RBD is significantly associated with...
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Alzheimer's Disease: Treatment
Insomnia
Multiple factors contribute...
Photoreceptors and Visual Pathways
